Plague Pipeline Report, H2 2016 - Therapeutics Review of 9 Companies & 19 Molecules - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Plague - Pipeline Review, H2 2016" report to their offering.

'Plague - Pipeline Review, H2 2016'; Plague pipeline therapeutics constitutes close to 19 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by the Universities/Institutes.

The report 'Plague - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Plague, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

It also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Plague Overview
  3. Therapeutics Development
  4. Pipeline Products for Plague - Overview
  5. Pipeline Products for Plague - Comparative Analysis
  6. Plague - Therapeutics under Development by Companies
  7. Plague - Therapeutics under Investigation by Universities/Institutes
  8. Plague Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Plague - Products under Development by Companies
  13. Plague - Products under Investigation by Universities/Institutes
  14. Plague - Companies Involved in Therapeutics Development
  • Aradigm Corporation
  • AvidBiotics Corp.
  • Endacea, Inc.
  • Grifols, S.A.
  • iBio, Inc.
  • Mucosis B.V.
  • Syntiron LLC
  • Takeda Pharmaceutical Company Limited
  • Tetraphase Pharmaceuticals Inc.

For more information about this report visit http://www.researchandmarkets.com/research/sk769k/plague_pipeline

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs